Market news

Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...

Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...

Detailed price information for Insulet Corp (PODD-Q) from The Globe and Mail including charting and trades.

ACTON, Mass., September 18, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).

Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF”. You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underperforming the Russell 2500 Growth Index’s 24.02% return. The trend towards “AI winners” continued, focusing on companies related to chips, […]

Detailed price information for Insulet Corp (PODD-Q) from The Globe and Mail including charting and trades.

PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a share price of US$148.38, Insulet has seen short term resilience with a 7 day share price return of 3.73%. However, the 30 day share price return is down 10.26% and the 1 year total shareholder return has declined 56.98%, which points to fading momentum as...

Overblown fears surrounding GLP-1 weight loss drugs were already pressuring the stock when an onboarding stumble triggered a sell-off.

Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid profitability. Click for more on PODD.

Opportunities include AI-enabled adherence platforms, connected inhalers, injectors and smart packaging, telehealth and home-care integration, chronic disease support, and pharmacy-led services in underserved and Asia-Pacific markets. Medication Adherence Market Medication Adherence Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Medication Adherence Market by Type of Solution, Type of Product, Route of Administration, Therapeutic Area, End-user, and Key Geographical Regions- Trends and Fo

ACTON, Mass., August 26, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time).

Insulet has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.

McEvoy invested $162,217 at a weighted average price of $147.47, bringing total beneficial ownership to 23,735 shares valued at $3.52 million.

Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to comm